Market Overview

UPDATE: Cantor Fitzgerald Initiates Coverage on Myriad Genetics on Position in Molecular Diagnostic Franchises

Related MYGN
Myriad myPath Melanoma Test Reduced Indeterminate Cases By 76% And Changed Treatment In 35 % Of Cases
Myriad Publishes myRisk Hereditary Cancer Study In Cancer

In a report published on Friday, analysts at Cantor Fitzgerald initiated coverage on Myriad Genetics (NASDAQ: MYGN) with a Buy rating and $40 PT.

In the report, lead analyst Sung Ji Nam commented that, "We are initiating coverage of MYGN with a BUY rating and $40 PT. With its current flagship product BRACAnalysis, MYGN has built one of the most successful, high-value molecular diagnostic franchises (~$500mm business), and we believe the company is well-positioned to execute industry-leading growth (top and bottom lines) over the next several years, driven by its competitive product portfolio and pipeline, as well as unmatched capabilities in diagnostic research, market development and commercialization capabilities."

Myriad Genetics closed on Thursday at $31.06

Latest Ratings for MYGN

DateFirmActionFromTo
Aug 2014Credit SuisseMaintainsNeutral
Jun 2014MacquarieMaintainsNeutral
May 2014Credit SuisseMaintainsNeutral

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Cantor Fitzgerald Sung Ji NamAnalyst Color Initiation Analyst Ratings

 

Related Articles (MYGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional